Archive for January, 2004

Biotech Limits Found Lacking

Biotech Limits Found Lacking Techniques for limiting the spread of genetically engineered salmon, corn and other organisms are still in their infancy, and far more work needs to be done to make sure the new products don’t taint the food supply or wipe out important species, a National Research Council panel said yesterday.


Click here for reuse options!
Copyright 2004 Biotechblog

FDA's economist in chief

FDA’s economist in chief Foes and friends of Mark McClellan agree on at least one point: The Food and Drug Administration commissioner is very popular with the drug industry he regulates. This article profiles opinions of Mark McClennan’s performance as FDA commissioner.


Click here for reuse options!
Copyright 2004 Biotechblog

FDA’s economist in chief

FDA’s economist in chief Foes and friends of Mark McClellan agree on at least one point: The Food and Drug Administration commissioner is very popular with the drug industry he regulates. This article profiles opinions of Mark McClennan’s performance as FDA commissioner.


Click here for reuse options!
Copyright 2004 Biotechblog

Biotech IPOs; don't let the numbers deceive

Biotech IPOs; don’t let the numbers deceive Take the biotechnology industry, which in 2003 raised $16.7 billion in capital — its second-best year ever. Yet, many of the biotech companies that went public in the last quarter of the year were miserable after-market performers.


Click here for reuse options!
Copyright 2004 Biotechblog

Biotech IPOs; don’t let the numbers deceive

Biotech IPOs; don’t let the numbers deceive Take the biotechnology industry, which in 2003 raised $16.7 billion in capital — its second-best year ever. Yet, many of the biotech companies that went public in the last quarter of the year were miserable after-market performers.


Click here for reuse options!
Copyright 2004 Biotechblog

Purple Haze

Purple Haze The prospects of a medicinal version of cannabis being produced have never been better but manufacturers are still trying to see through the haze of ethical and practical issues.


Click here for reuse options!
Copyright 2004 Biotechblog

What's Next for Pharma?

What’s Next for Pharma? Experts from the Tufts Center for the Study of Drug Development discuss the outlook for R&D, mergers, and the FDA’s changing role


Click here for reuse options!
Copyright 2004 Biotechblog

What’s Next for Pharma?

What’s Next for Pharma? Experts from the Tufts Center for the Study of Drug Development discuss the outlook for R&D, mergers, and the FDA’s changing role


Click here for reuse options!
Copyright 2004 Biotechblog

India: Big Pharma's New Promised Land?

India: Big Pharma’s New Promised Land? For years, software companies have known that they can slash costs by hiring eager, smart, and inexpensive programmers and engineers in India. Following in software’s footsteps, corporations providing telephone support and back-office services soon saw the virtues of India’s well-trained workforce as well. Now, Big Pharma is discovering the […]


Click here for reuse options!
Copyright 2004 Biotechblog

%d bloggers like this: